Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-15T18:27:26.599Z Has data issue: false hasContentIssue false
  • English
  • Français

Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset

Published online by Cambridge University Press:  23 March 2020

G. Fond ,
M. Favez ,
L. Boyer ,
L. Pierre-Michel ,
A. Pelissolo  and
F. Berna
G. Fond
Affiliation:
Schizophrenia expert, center Fondation fondamental, Creteil, France
M. Favez
Affiliation:
Schizophrenia expert, center Fondation fondamental, Creteil, France
L. Boyer
Affiliation:
Pôle psychiatrie universitaire - CHU Sainte-Marguerite, pôle psychiatrie universitaire, Marseille, France
L. Pierre-Michel
Affiliation:
Schizophrenia expert, center Fondation fondamental, Clermont-Ferrand, France
A. Pelissolo
Affiliation:
Schizophrenia expert, center Fondation fondamental, Creteil, France
F. Berna*
Affiliation:
Hôpitaux universitaires de Strasbourg- Inserm U1114- FMTS- Fondation FondaMental, psychiatry, Strasbourg cedex, France
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The primary objective of this study was to determine if second generation antipsychotic (SGA) administration was associated with lower aggressiveness scores compared to first generation (FGA) in schizophrenia (SZ). The secondary objective was to determine if antidepressants, mood stabilizers and benzodiazepines administration were respectively associated with lower aggressiveness scores compared to patients who were not administered these medications.

Methods

Three hundred and thirty-one patients with schizophrenia (n = 255) or schizoaffective disorder (n = 76) (mean age = 32.5 years, 75.5% male gender) were systematically included in the network of FondaMental Expert Center for Schizophrenia and assessed with the Structured Clinical Interview for DSM-IV Axis I Disorders and validated scales for psychotic symptomatology, insight and compliance. Aggressiveness was measured by the Buss-Perry Aggression Questionnaire (BPAQ) score. Ongoing psychotropic treatment was recorded.

Results

Patients who received SGA had lower BPAQ scores than patients who did not (P = 0.01). On the contrary, patients who received benzodiazepines had higher BPAQ scores than patients who did not (P = 0.04). These results were found independently of socio-demographical variables, psychotic symptomatology, insight, compliance into treatment, daily-administered antipsychotic dose, the way of antipsychotic administration (oral vs long acting), current alcohol disorder and daily cannabis consumption.

Conclusion

The results of the present study are in favor of the choice of SGA in SZ patients with aggressiveness, but these results need further investigation in longitudinal studies. Given the potent side effects of benzodiazepines (especially dependency and cognitive impairment) and the results of the present study, their long-term prescription is not recommended in patients with schizophrenia and aggressive behavior.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW493
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. s242 - s243
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.